Julian Baines

James McCullough

Dr. Erik Lium

Sara Barrington

Sir Ian Carruthers, OBE

Dr Lorenzo Gallon, MD

Useful Links

Get in touch

Vox Markets Podcast

Verici Dx plc

Q&A with Verici DX

Albeit still a relatively small business (£5.1m mrkcap), Verici Dx certainly punches above it weight. Today announcing that in Q4'26, it plans to launch a new "1st-in-class" genetic RNA blood test TranscripTx.

Verici Dx to Launch TranscripTx™ Transplant Genetic Test in Q4 2026

Precision medicine is steadily replacing healthcare’s old 'one-size-fits-all' playbook. Indeed by using genomic sequencing and protein biomarkers to understand a patient's specific condition, doctors can choose personalised therapies that improve efficacy and outcomes, while equally avoiding unnecessary treatment, toxicity and side effects.

Verici Dx Achieves Olink Certified Service Provider Status

In this upbeat interview, CEO Sara Barrington of Verici DX – a next generation medical diagnostics firm focusing on the global kidney transplant market - takes me through last week’s ‘in line’ FY’25 results and positive outlook.

Q&A with Verici DX CEO Sara Barrington

One of the toughest challenges remaining in US healthcare is to improve the success rates of kidney transplants. Not only reducing the number of acute organ rejections (10% in year 1) and enhancing patient care, but also cutting hospital costs and eliminating expensive dialysis (Est $100k pa) and poorly targeted immunosuppression.

Verici Dx Secures New York State Clinical Lab Certification

One of the best untapped opportunities in US healthcare is to improve outcomes for kidney transplant patients, whilst simultaneously reducing the enormous cost burden of organ rejection, repeat hospitalisations, dialysis and over/under immunosuppression.

Verici Dx Reports Progress Across Kidney Transplant Diagnostics Portfolio

Kidney transplants are one of medicine’s great success stories, but they still come with a frustratingly blunt follow-up toolkit. Too little immunosuppressant and the new kidney can be rejected. Too much and the patient faces higher risks of toxicity, infection and even malignancy.

Verici Dx Announces Publication of PTRA Clinical Validation Study

hVIVO Plc.

Poolbeg Pharma plc

Keeping you informed with the latest company updates and investment insights from renowned stock market professionals

Vox Markets Video Wrap

After >5 years of hard graft and substantial progress since its Dec’20 IPO, the stars are aligning for AI-powered kidney transplant diagnostics firm Verici Dx.

Verici Dx Reports Positive Q1 Trading Update

In this upbeat interview, CEO Sara Barrington of Verici DX – a next generation medical diagnostics firm focusing on the global kidney transplant market - takes me through today’s positive and better than expected Q1’26 trading update.

Interview with Verici Dx CEO Sara Barrington

In this upbeat interview, CEO Sara Barrington of Verici DX – a next generation medical diagnostics firm focusing on the global kidney transplant market - takes me through today's positive FY'25 trading update, alongside progress wrt the company's exciting growth trajectory.

Q&A with Verici Dx CEO Sara Barrington

After a challenging 3-4 years, prospects across the medical diagnostics industry appear to be improving as evidenced by increased M&A activity and rising valuations. Indeed only in Nov’25, Abbott Laboratories snapped up Exact Sciences, the maker of colon cancer test Cologuard for $23bn, or 6.2x EV/sales.

Verici Dx: A Year of Strong Growth and Commercial Progress

Asiamet Resources Ltd.

Aura Energy Limited NPV (DI)

Corcel Exploration Inc.

Seeing Machines Ltd.

Our daily digest of news from UK Small Caps

It wouldn’t be an overstatement to say that since Donald Trump has become President, the US healthcare system has been in an acute state of flux. Experiencing intense pressure from not only lower drug prices, reshoring threats & import tariffs, but also disruption across the whole insurance system (re ending of Obamacare enhanced subsidies in Dec’25) as this issue is being hotly debated in Congress and led to the current 37 day government shutdown (ie longest in history).

Verici Dx Announces Provider Participation Agreement with Prime Health Services

In this upbeat interview, CEO Sara Barrington of Verici DX – a next generation medical diagnostics firm focusing on the global kidney transplant market - takes me through: Progress on #VRCI’s commercialisation strategy following July’s £6.35m fund raise and Monday’s in line H1’25 results.

Interview with CEO, Sara Barrington of Verici DX

Verici Dx’s name (probably) derives from combining the words “verity” (truth) and “diagnostics” – together meaning the “truth in medical testing.”

Verici Dx: 9 new transplant centres on-boarded & 19% increase in ordering clinicians in Q3

AIREA

Malvern International

Watkin Jones

Hybridan Small Cap Feast: 30/09/2025

According to the late, great Charlie Munger: “Investing is simple, but not easy”. The difficult part is not the number crunching, but instead the ability to identify hidden value which is not yet reflected in the accounts such as patents, regulatory approvals, customer feedback and importantly future profitable growth.

Verici Dx: Significant commercial progress with first revenues from Tutivia™ test sales

In this upbeat interview, CEO Sara Barrington of Verici DX – a next generation medical diagnostics firm focusing on the global kidney transplant market - takes me through:
Verici's £6.35m recent fund raise and planned use of proceeds. Commercialisation of its flagship blood test Tutivia.
$300m total addressable market for Tutivia
Relationship with Thermo Fisher Scientific (re pre-graft Clarava/PTRA test)
Update on 3rd diagnostic (Protega) and closing remarks

'Demand pull' combined with 'supply push' are two simple yet crucial ways for businesses to commercialise new breakthrough offerings. Not only ‘showcasing’ the products’ benefits and educating key opinion leaders. But also, ensuring the goods are readily available for customers to buy and use correctly, straight out the box.

Verici Dx plc

Latest Coverage

Q&A with Verici DX

Verici Dx to Launch TranscripTx™ Transplant Genetic Test in Q4 2026

Verici Dx Achieves Olink Certified Service Provider Status

Q&A with Verici DX CEO Sara Barrington

Overview

Company Profile

Classification